However, cultures established with the BM concentrate exhibited higher mean MTT reduction values at all tested time-points and also a higher growth rate, especially from days 17 to 23; maximum values were achieved by day 23 and, after that, cell proliferation decreased slowly.
No significant difference was identified in the mean PUSH score reduction values in either cohort from immediately after the start of observations to the second week, from the second to the fourth week, from the fourth to the sixth week, from the sixth to the eighth week, from the eighth to the 10th week and from the 10th to the 12th week (table 2).
Although between-group differences in the adjusted mean reduction in M value were not statistically significant (Fig. 2 C ), insulin glargine treated patients experienced significant reductions from baseline at weeks 12 (P = 0.0309) and 24 (P = 0.0048) (Table 3).
Results showed significant reductions in S. mutans/sobrinus levels pre- to post-intervention for the xylitol groups as well as for the maltitol group (group, log10 mean reduction [SD], p-value: X16, 1.13 [1.65], p < 0.0001; X12, 0.89 [1.11], p < 0.0001; and M45, 0.91 [1.46], p < 0.0001, Table 2 & Figure 2).
The FECR following ivermectin treatment varied from 0-100%, with a mean reduction of 50% (transformed values) and 36% (individual FECRs) (table 2).
At 20 months after crosslinking, there was a mean reduction in simulated keratometry values by 0.66 D in the flattest meridian and by 0.72 D in the steepest meridian.
Experiments were carried out in quadruplicate under dirty conditions; lowest log10 reduction values or mean and standard deviation are shown.
Based on those values, volume mean reduction potential was 58.8%.
Mean reductions in FPG values were similar across treatment groups (IDegAsp = 122 mg/dL [6.8 mmol/L], AF = 133 mg/dL [7.4 mmol/L], IGlar = 126 mg/dL [7.0 mmol/L]).
The arithmetic means of all individual log10 reduction values were calculated.
